Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
|Videos|August 19, 2013
Why Do Manufacturers Limit the Distribution of Certain Specialty Drugs?
Some pharmaceutical manufacturers choose a limited distribution model for their specialty product so that they can ensure all standards of care and reporting associated with that therapy are upheld, noted Duane Barnes, senior vice president, consumer delivery, Prime Therapeutics, at the 2013 Armada Specialty Pharmacy Summit.
Advertisement
Some pharmaceutical manufacturers choose a limited distribution model for their specialty product so that they can ensure all standards of care and reporting associated with that therapy are upheld, noted Duane Barnes, senior vice president, consumer delivery, Prime Therapeutics, at the 2013 Armada Specialty Pharmacy Summit.
Advertisement
Related to this article
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Prescription Volume: Measuring the Pharmacist’s Value
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5